SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 19, 2002
United Therapeutics Corporation
| Delaware | 000-26301 | 52-1984749 | ||
|
|
||||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
| 1110 Spring Street Silver Spring, MD |
20910 | ||||
|
|
|||||
| (Address of Principal Executive Offices) | (Zip Code) | ||||
Registrant’s telephone number, including area code:
(301) 608-9292
Item 5. Other Events.
On August 19, 2002, United Therapeutics Corporation (the “Company”) issued a press release announcing that Dr. Martine A. Rothblatt, the Chairman and Chief Executive Officer of the Company, entered into a trading plan in compliance with Rule 10b5-1. A copy of the press release is attached hereto and incorporated herein by this reference.
Item 7. Exhibits
(c) Exhibits
| Exhibit No | Description of Exhibit | |
|
|
||
| 99.1 | Press release dated August 19, 2002. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| UNITED THERAPEUTICS CORPORATION | ||||
| Dated: | August 19, 2002 | By: /s/ Paul A. Mahon
Name: Paul A. Mahon Title: Senior V.P. and General Counsel |
EXHIBIT INDEX
| Exhibit No | Description of Exhibit | |
|
|
||
| 99.1 | Press release dated August 19, 2002. |